Key takeaways: 27% of respondents noticed changes to their menstrual cycle since starting GLP-1 medication for weight loss Respondents with PCOS were more likely to experience cycle changes, and 43% of this group reported noticing changes to their menstrual cycle The most commonly reported cycle changes were more predictable periods, more frequent periods, and shorter periods GLP-1 medications like semaglutide (Ozempic) and tirzepatide (Mounjaro) have traditionally been used to treat diabetes
Combination Research: CJC-1295 + Ipamorelin One of the most widely studied peptide combinations in GH research is CJC-1295 + Ipamorelin
We reasoned that combining triple treatment, the approach which caused the largest increase in GLP1, with an oral glucose challenge, which should further increase GLP1, could potentially uncover a protective effect of increased endogenous GLP1 against olanzapine-induced perturbations in glucose homeostasis
In SURMOUNT-1, non-diabetic patients lost up to 21% of body weight
A recent 27 real-world study reported weight loss outcomes of semaglutide use in patients with or without a previous history of bariatric surgery
Warnings The recommended daily dose should not be exceeded and the product should be kept out of the reach of children